sponsored by the Rotta Research Laboratorium and used that company's formulation of glucosamine sulphate'. Surely this implies some considerable bias. Secondly, because no glucosamine product in Australia has an AUST R rating by the Therapeutic Goods Administration, does this not also imply that the products in Australia may be subject to qualitative and quantitative variations to the product studied and therefore may not produce the same or any therapeutic effect? This point is implied by the author who states 'this formulation may differ from those available in Australia'.
While glucosamine may have a unique mechanism of action, is this not thrown into doubt by the 'poor correlation between structural and symptomatic responses'? Regardless, where are the well-designed comparative trials necessary to show that glucosamine is better than standard therapy?
Previous comparative trials were poorly designed, of short duration and involved small numbers.
Derek Grubb Pharmacy Department Bunbury Regional Hospital Bunbury, WA Associate Professor G. McColl, the author of the article, comments:
Both of the major randomised controlled studies were sponsored by the Rotta Research Laboratorium and this may have introduced bias into the studies. This notion, of course, would also have to apply to the majority of medications available on the Pharmaceutical Benefits Scheme, as the studies supporting their listing would also have been supported by their manufacturers.
The issue of 'qualitative and quantitative' variation in glucosamine products available in Australia is a significant one. In the purest view of evidence-based medicine we should only use the preparation that was tested in the study.
As the Rotta glucosamine product is difficult to access in Australia this creates a problem. In practical terms, however, it is reasonable to extrapolate the data from these studies to 'reputable' glucosamine products in Australia, particularly if a therapeutic trial of three months is recommended.
No high quality trial has compared routine therapies such as paracetamol or non-steroidal anti-inflammatory drugs to glucosamine. I agree that this is a deficiency and will hopefully be addressed by a current study sponsored by the National Institutes of Health in the USA. The Preface suggests that the handbook may be used as a learning tool for students -the clinical approach would provide a good structure for students to base their learning upon.
Book review
However, the information has been well summarised and medical students are likely to need more detailed references.
I found this book to be a useful and practical addition to the available information resources for general practice. Its compact size makes it portable enough to carry to home visits and on the ward. It is a well designed tool to support the practice of evidence-based medicine.
